These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 29236146)

  • 1. [Atherothrombosis : Novel therapeutic strategies].
    Soehnlein O
    Herz; 2018 Mar; 43(2):103-108. PubMed ID: 29236146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future.
    Weber C; Badimon L; Mach F; van der Vorst EPC
    Thromb Haemost; 2017 Jun; 117(7):1258-1264. PubMed ID: 28594053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
    Chapman MJ
    Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor XI regulates pathological thrombus formation on acutely ruptured atherosclerotic plaques.
    van Montfoort ML; Kuijpers MJ; Knaup VL; Bhanot S; Monia BP; Roelofs JJ; Heemskerk JW; Meijers JC
    Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1668-73. PubMed ID: 24947525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review: the physiological and computational approaches for atherosclerosis treatment.
    Wang W; Lee Y; Lee CH
    Int J Cardiol; 2013 Sep; 167(5):1664-76. PubMed ID: 23103138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical significance of and treatment options for increased lipoprotein(a)].
    Zsíros N; Paragh G; Harangi M
    Orv Hetil; 2014 Apr; 155(16):607-14. PubMed ID: 24733102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.
    Navarese EP; Kołodziejczak M; Dimitroulis D; Wolff G; Busch HL; Devito F; Sionis A; Ciccone MM
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):44-53. PubMed ID: 27533061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vulnerable plaque and inflammation: potential clinical strategies.
    Drakopoulou M; Toutouzas K; Michelongona A; Tousoulis D; Stefanadis C
    Curr Pharm Des; 2011 Dec; 17(37):4190-209. PubMed ID: 22204378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future.
    Hajhosseiny R; Sabir I; Khavandi K; Wierzbicki AS
    Clin Pharmacol Ther; 2014 Jul; 96(1):64-73. PubMed ID: 24699033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the unstable plaque in acute coronary syndromes.
    Thompson PL; Nidorf SM; Eikelboom J
    Clin Ther; 2013 Aug; 35(8):1099-107. PubMed ID: 23973042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy.
    McLaren JE; Michael DR; Ashlin TG; Ramji DP
    Prog Lipid Res; 2011 Oct; 50(4):331-47. PubMed ID: 21601592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCSK9 inhibitors- A new age in lipid management?
    Grant PJ
    Diab Vasc Dis Res; 2017 May; 14(3):171. PubMed ID: 28467196
    [No Abstract]   [Full Text] [Related]  

  • 15. Protease-Activated Receptor 1 Inhibitors: Novel Antiplatelet Drugs in Prevention of Atherothrombosis.
    Al-Khafaji K; Mutyala M; Al-Khafaji N; Harper Y; Ismail I; Hakim H; Arora RR
    Am J Ther; 2017; 24(6):e730-e736. PubMed ID: 26398717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is clonal hematopoiesis a new risk factor for cardiovascular diseases?: Clinical and experimental evidences.
    Páramo Fernandez JA
    Med Clin (Barc); 2018 Sep; 151(5):207-209. PubMed ID: 29802011
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
    Auer J; Berent R
    Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of lipid management in acute coronary syndrome.
    Fujisue K; Tsujita K
    J Cardiol; 2017 Aug; 70(2):101-106. PubMed ID: 28325524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables.
    Feher G; Koltai K; Papp E; Alkonyi B; Solyom A; Kenyeres P; Kesmarky G; Czopf L; Toth K
    Drugs Aging; 2006; 23(7):559-67. PubMed ID: 16930084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.